Grant: Operating Grant: Industry-partnered Collaborative Research - Rx&D partner
McGill University
$178,125.00
Effects of S1P receptor directed pharmaceutical agents on central nervous system myelination
EF 2010-11
Résumé
The neurologic disorder multiple sclerosis (MS) involves injury and destruction of the myelin membrane that ensheaths nerve fibers (axons) and is required for efficient electrical conduction with the central nervous system (CNS). We postulate that the overall extent of neurologic dysfunction in MS patients reflects both the extent of injury of myelin and its cell of origin the oligodendrocyte (OL) and the extent of repair mediated by OL progenitor cells (OPCs). FTY720 is a sphingosine-1phosphate receptor (S1PR) agonist about to enter clinical use in MS because of its effects on the peripheral immune system. As this agent can access the central nervous system (CNS) and S1PRs are expressed on all cells of the CNS, we ask what effects FTY720 and related SIPR directed agents will have on protecting OLs from injury in MS and on the capacity of OPCs to contribute to repair.
Programme
Operating Grant: Industry-partnered Collaborative Research - Rx&D partner
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
221592
Name
Antel Jack P
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Biomedical
Prcname2
Industry Partnered Collaborative Research
Projecttitle
Effects of S1P receptor directed pharmaceutical agents on central nervous system myelination
Programtype2
Operating Grants
Orgnameinp2
McGill University
Cihramount2
$178,125
Cihrequipment2
$0
Programname2
Operating Grant: Industry-partnered Collaborative Research - Rx&D partner
Keyworddelim
Central Nervous System; Multiple Sclerosis; Myelin; Oligodendrocytes; S1p Receptors
Abstract
The neurologic disorder multiple sclerosis (MS) involves injury and destruction of the myelin membrane that ensheaths nerve fibers (axons) and is required for efficient electrical conduction with the central nervous system (CNS). We postulate that the overall extent of neurologic dysfunction in MS patients reflects both the extent of injury of myelin and its cell of origin the oligodendrocyte (OL) and the extent of repair mediated by OL progenitor cells (OPCs). FTY720 is a sphingosine-1phosphate receptor (S1PR) agonist about to enter clinical use in MS because of its effects on the peripheral immune system. As this agent can access the central nervous system (CNS) and S1PRs are expressed on all cells of the CNS, we ask what effects FTY720 and related SIPR directed agents will have on protecting OLs from injury in MS and on the capacity of OPCs to contribute to repair.
Competitiondate
201009
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Antel, Jack P
Approvedterm
3 ans 0 mois
Cihrcontribution2
Patient Oriented Research~ $178,125~ $0~